NCT06821334

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

A Randomized, Double-Blind, Placebo-Controlled Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics of MK-6194 in Healthy Chinese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to learn how safe MK-6194 is in healthy Chinese adults and how well people tolerate it.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	MK-6194	Subcutaneous Administration
BIOLOGICAL	Placebo	Subcutaneous administration

Timeline

• Start date: 2024-04-23
• Primary completion: 2024-08-09
• Completion: 2024-08-09
• First posted: 2025-02-12
• Last updated: 2025-02-12

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study